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Summary
Objective: To assess changes in incidence and in antibiotic prescription rates for infections of the
lower respiratory tract (LRTI) and urinary tract (UTI) in patients with diabetes (DM) over the years
1995 to 2003.
Methods: This was a retrospective cohort study as part of the University Medical Center Utrecht
General Practitioners Research Network. We included patients with DM aged 45 years. We
assessed incidence and antibiotic prescription rates for LRTI and UTI. Incidence rates were
calculated as episodes per 1000 person-years. Antibiotic prescription rates were calculated per
100 episodes of LRTI and UTI.
Results: The study population increased over the years 1995 to 2003. The male-to-female ratio
and mean age of the study population remained constant over these years. The incidence rate for
LRTI remained stable (13%; p = 0.442), and for UTI the incidence rate increased by 40%
(p = 0.037). Antibiotic prescription rates increased in LRTI by 60% ( p < 0.001) and in cystitis
by 15% (p = 0.029).
Conclusions: Incidence rates for UTI and antibiotic prescription rates for LRTI in diabetes have
increased over the years 1995 to 2003. In particular, attention should be paid to the increasing use
of antibiotics in DM patients with LRTI.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +31 30 2538181/8154;
fax: +31 30 2539028.
E-mail address: e.hak@umcutrecht.nl (E. Hak).
1201-9712/$36.00 # 2009 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2008.12.003Introduction
Patients with diabetes (DM) have an increased risk of urinary
tract infections (UTI) and lower respiratory tract infections
(LRTI), in particular when they are treated with oral diabetes
medication or insulin.1—5 Also, common infections may be
more difficult to treat and often recur, and diabetes evenPublished by Elsevier Ltd. All rights reserved.
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tions.6—9 However, specific guidelines on the prevention and
treatment of UTI and LRTI in diabetes are lacking.1
In the Netherlands, trimethoprim and nitrofurantoin have
been the first choice treatment for UTI since 1989, and from
1989 to 1999 sulfamethizole was an additional alternative.10
Regarding exacerbations of chronic obstructive pulmonary
disease (COPD), since 1997, antibiotics (amoxicillin, doxycy-
cline, or other broad-spectrum antibiotics) have only been
advised in high-risk cases.11 In 30% of consultations for LRTI
an antibiotic is prescribed, and over the last 10 years a shift
towards more costly, broad-spectrum antibiotic usage in
outpatient care has occurred,12 although in general, tradi-
tional antibiotics provide similar outcomes compared to the
newer ones.13,14
Any benefit from antibiotics must be weighed against
the possibility that excessive antibiotic use will increase
patient morbidity and enhance antimicrobial resis-
tance.15—17 In studying prescription rates, both the number
of prescriptions and the incidence of the diseases under
study have to be taken into account. Such data will help in
making decisions about treatment and will allow health
education programs to be tailored to diabetes care provi-
ders and patients. However, changes in the prescription of
antibiotics for common infections in patients with DM over a
period of several years are unknown. Therefore, we sought
to assess the changes in incidence and in antibiotic pre-
scription rates for LRTI and UTI in patients with DM over a
number of years.
Methods
Patients
A retrospective cohort study was conducted using data from
the computerizedmedical database of the University Medical
Center Utrecht General Practitioners Research Network. This
database consists of prospectively collected information on a
cumulative primary care population of approximately 60 000
patients over the years 1989 to 2004. From 1995 onwards,
medical data of all patients enlisted were recorded using a
uniform, structured, contact registration in the general
practitioner information system (GPIS) ELIAS1 (iSOFT).
Approximately 35 participating general practitioners (GPs)
received continuedmedical education from staff at the Julius
Center of Health Sciences and Primary Care regarding the
correct coding of diagnostic information according to the
International Classification of Primary Care coding system
(ICPC).18 GPs received feedback about the quality of regis-
tration (i.e., the proportion of contacts with an ICPC code).
Ultimately, more than 90% of contacts received an ICPC code,
and accuracy appears high and was insured through financial
arrangements. All prescriptions were recorded in the
database, including drug name, Anatomical Therapeutic
Chemical (ATC) classification code,19 dosage form, dose,
and prescribed quantity. Decisions concerning diagnosis
and treatment were left to the discretion of the GP. Patients
and GP identifiers were recorded to ensure anonymity. The
system complies with Dutch guidelines on the use of medical
data for research purposes and has been shown to be valid in
pharmaco-epidemiological studies.20,21Patients aged 45 years or older recorded in the GPIS with
diabetes (ICPC code T90) were included. No patients were
excluded.
Outcomes
The outcomes investigated were episodes of LRTI and UTI,
rates of antibiotic prescription, and rates of type of anti-
biotic prescribed. LRTI was defined as pneumonia (R81),
acute bronchitis (R78), and exacerbations of chronic bron-
chitis, COPD, or asthma. Exacerbations were recorded by
GPs by the use of R78 in cases of chronic bronchitis, asthma,
or COPD.22 UTI was defined as cystitis (U71), prostatitis
(Y73), or acute pyelonephritis (U70). A new episode was
recorded if a patient was free of complaints for a period of 28
days. We did not differentiate between a first episode, a
relapse, or a recurrence of a registered infection. Since
there was no direct link in the database between a disease
episode and antibiotic prescription, we defined a time win-
dowbeginning seven days before and ending seven days after
the diagnosis.
Antibiotics prescribed for LRTI were classified into the
following main categories: (1) broad-spectrum penicillins
(J01CA/R): amoxicillin (J01CA04) and co-amoxiclav
(J01CR02); (2) tetracyclines (J01AA): doxycycline
(J01AA02); (3) macrolides (J01FA); (4) sulfonamides and
trimethoprim (J01E); (5) other: quinolones (J01MA), fluclox-
acillin (J01CF), and cephalosporins (J01D). The classification
of antibiotics used for UTI was: (1) broad-spectrum penicillins
(J01CA/R): amoxicillin (J01CA04) and co-amoxiclav
(J01CR02); (2) quinolones (J01MA); (3) sulfonamides and
trimethoprim (J01E); (4) nitrofurantoin (J01XE); (5) other:
tetracyclines (J01AA), macrolides (J01FA), flucloxacillin
(J01CF), and cephalosporins (J01D).
Statistical analysis
Annual incidence rates of presented episodes of infections
were calculated per 1000 person-years by dividing the
number of UTI and LRTI episodes by the total number of
person-years in a specific year. Average incidence rates
were calculated for all years combined. Antibiotic pre-
scription rates were calculated as the number and type
of prescriptions per 100 episodes of UTI and LRTI registered
by the GP. Changes between 1995 and 2003 were studied by
nine-year risk differences with 95% confidence intervals
(CI). Subgroup analysis was done for patients with diabetes
who did and did not use insulin, because previous studies
have shown that the risk of infection is even more
increased in insulin-using diabetes patients.1,4 We used
SPSS version 12.0 (SPSS Inc., Chicago, USA) for all statis-
tical analyses.
Results
The study population increased over the years 1995 to 2003.
The male-to-female ratio and mean age of the study popu-
lation remained constant over these years. The use of
insulin and of oral diabetes medication increased over
the years from 7% to 14% and from 45% to 62%, respectively
(Table 1).
Figure 1 Incidence of lower respiratory tract infection (LRTI) per 1000 person-years.
Table 1 Study population
Year N Mean age  SD Female Use of insulin Use of oral diabetes medication
1995 721 68.6  10.9 53.4 7.2 44.8
1996 906 68.8  11.1 53.6 9.3 48.8
1997 1066 68.8  11.1 53.1 10.6 52.6
1998 1221 69.1  11.0 52.2 11.5 52.3
1999 1308 68.7  11.1 52.5 11.9 54.7
2000 1393 68.7  11.2 52.7 11.5 54.2
2001 1458 68.9  11.2 53.5 13.2 58.0
2002 1544 69.0  11.2 52.9 13.9 58.7
2003 1624 68.9  11.1 52.3 13.8 61.9
Percentages unless otherwise specified.
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The overall LRTI incidence rate remained stable (13%;
p = 0.442), with 78 episodes per 1000 person-years (95% CI:
62—97%) in 1995 and 88 episodes per 1000 person-years in
2003 (95% CI: 71—108). The incidence rates for the different
types of LRTI are shown in Figure 1. The relative risk of
presenting to the GP with an infection in patients using
insulin compared to those not using insulin varied across
the years (range: 0.5 in 1995 to 1.9 in 1996; Figure 1).
Antibiotic prescription for LRTI increased significantly
from 42 per 100 episodes (95% CI: 33—52%) in 1995 to 67
(95% CI: 57—75%) in 2003, an increase of 60% ( p < 0.001). The
rate of doxycycline prescribed increased by 330% ( p < 0.001)
over the years 1995 to 2003. The rate of amoxicillin pre-
scription decreased (52%; p = 0.051), whereas the rate of co-
amoxiclav prescription increased (180%; p = 0.062) and theFigure 2 Antibiotic prescription and first choice antibiotics prescrirate of prescribed macrolides varied across the years, but
overall increased by 186% ( p = 0.127) (Figure 2).
UTI incidence and treatment
UTI incidence rates increased significantly from 72 episodes
per 1000 person-years (95% CI: 57—90%) in 1995 to 101
episodes per 1000 person-years in 2003 (95% CI: 83—122%),
an increase of 40% ( p = 0.037). This increase was due to a
more frequent presentation of episodes of cystitis; the inci-
dence rates of prostatitis and acute pyelonephritis remained
stable. The relative risks were greater in patients using
insulin compared with those not using insulin (range: 1.2
in 2002 to 3.0 in 2001; Figure 3).
The antibiotic prescription rate for cystitis increased from
78 per 100 episodes (95% CI: 69—85%) in 1995 to 90 (95% CI:
83—94%) in 2003, an increase of 15% ( p = 0.029). Due to lowbed per 100 episodes of lower respiratory tract infection (LRTI).
Figure 3 Incidence of urinary tract infection (UTI) per 1000 person-years.
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rates for prostatitis and acute pyelonephritis. The rate of
broad-spectrum antibiotic use was about the same across the
years, with a decrease in amoxicillin (71%; p = 0.036) and an
increase in co-amoxiclav (160%; p = 0.395). The rate of pre-
scribed sulfonamides and trimethoprim and also the rate of
quinolones prescribed varied across the years, but overall
decreased by 57% ( p = 0.032) and 29% ( p = 0.313), respec-
tively. The rate of nitrofurantoin prescription increased by
480% ( p < 0.001) (Figure 4).Discussion
From 1995 to 2003, the incidence rate of UTI occurring in a
Dutch primary care setting increased by 40%. Relative risks
were greater in patients with UTI who used insulin compared
with those who did not use insulin (range: 1.2 in 2002 to 3.0 in
2001). Antibiotic prescription rates increased in LRTI by 60%,
which may enhance antibiotic resistance. The rate of doxycy-
cline prescribed for LRTI increased by 330%, and for cystitis,
the rate of prescribed nitrofurantoin increased by 480%.
Figure 4 Antibiotic prescription and first choice antibiotics prescribed per 100 episodes of urinary tract infection (UTI).
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rates for common infections and antibiotic prescription rates
in an unselected population of patients with DM over a long
period of time.Whenmonitoring national figures of antibiotic
prescription, it is sensible to use figures relating to periods of
several years, because of yearly variations. Other strengths
of our study were the use of multiple outcomes and the
quality of the data registered by GPs. Most characteristics of
the population remained unchanged over the study years, but
glycemic control possibly improved as a result of higher
numbers of prescriptions for insulin therapy. If anything, this
change would have led to declines in our outcomes, hence
the observed increases in UTI and LRTI episodes may even be
underestimates.
Because of lacking data on the combination ‘diabetes
and infections’, we are unable to compare our incidence
and antibiotic prescribing rates with those of others. How-
ever, information is available on the incidence of UTI and
LRTI and antibiotic prescription in general. In the UK, the
incidence of LRTI fell between 1994 and 2000 and there
were minimal reductions in the incidence of UTI.23 Since
2000, consultation rates for LRTI have shown evidence ofstabilizing.24 Compared with our findings, an earlier study
in the Netherlands found a lower GP consultation rate for
LRTI in the general population during a 12-month period
between May 2000 and April 2002: 44 per 1000 person-
years.22 It is difficult to accurately compare UTI incidences
because for example, in the USA, UTI are not reportable
diseases.25 Our findings, an increase in the incidence of
cystitis and a stabilization of the incidence of acute pye-
lonephritis, are comparable with findings in the general
population, i.e., people with and without diabetes, from
1995 to 1999.26
In the Netherlands, antibiotic prescribing rates are low
compared with other European countries and the USA.27,28
However, Dutch GPs do not appear to be reluctant in pre-
scribing antibiotics for LRTI, especially in acute bronchitis. In
the general population, they are likely to prescribe at the
same rates as their colleagues in the UK and the USA.29 In the
Netherlands, antibiotic prescribing was not in accordance
with the recommendations of the guidelines in 63% of the
consultations for bronchitis.12 We found a strong increase in
the rate of prescribed antibiotics for LRTI. This increase
might be explained by a decrease in the ‘wait and see’
e350 L.M.A.J. Venmans et al.attitude of the GP if patients with DM present themselves
with a recurrent LRTI.
In 2003, doxycycline and co-amoxiclav were the
two most prescribed antibiotics for LRTI. The rate of
macrolide use for LRTI in diabetes varied across the years,
but overall increased. This is noteworthy, because this
type of antibiotic should not be a first choice treatment
in Dutch general practice and is linked to a risk of growing
resistance in relevant bacterial pathogens.30 In UTI, the
rate of nitrofurantoin use strongly increased, especially in
the last few years. A likely explanation is that in 1999,
sulfamethizole ceased to be the first-line treatment in
the guidelines for Dutch GPs.10 Internationally, trimetho-
prim has been suggested as the first choice of treatment
for women with UTI, except in communities with a high
rate of resistance, when the local guidance should be
followed.31 In the US, ambulatory care physicians are
increasing their use of fluoroquinolones and nitrofurantoin,
even though they claim that these antibiotics are not
highly recommended and not the most cost-effective.32
In the UK, trimethoprim was the most commonly used
antibiotic for episodes of uncomplicated cystitis.33 Over
the years we found a slight decrease in the rate of qui-
nolone use for UTI in diabetes. This is important and
reassuring because of the increasing resistance of Escher-
ichia coli to these antibiotics.34
Some limitations should be discussed. First, our study was
based on patients visiting their GP, which may underestimate
the true incidence rates in the general population. Second,
misclassification due to missing data and differences in clas-
sification between years and GPs cannot be ruled out and this
may have resulted in either an over- or under-estimation of
the true incidence rates. It is, however, unlikely that this
misclassification has affected the results substantially, since
up to 90% of all patient contacts were coded. Third, we did
not differentiate between patients with type 1 and type 2
diabetes. We think that most patients in our study had type 2
diabetes, because the mean age of the study population was
69 years. Fourth, we had inadequate power to analyze a large
number of subgroups, for example, we were not able to study
antibiotic prescription rates in prostatitis and acute pyelone-
phritis.
No evidence-based guidelines are available on the treat-
ment of common infections in diabetes. Most recommenda-
tions for the treatment of UTI in diabetes are based on expert
opinions.6 Some authors suggest that all UTI in patients with
DM should be treated as complicated infections, while others
think that the term ‘complicated’ should be reserved for
(diabetic) patients with persistent or recurrent infections or
for example abnormalities of the urinary tract or impaired
renal function.6 Since evidence is lacking at the moment, we
would recommend that treatment be tailored to patients
with DM at high risk for a complicated course of infection. For
that reason, we have developed prediction models for a
complicated course of UTI and LRTI.35,36 Randomized trials
are needed to compare the optimal duration and the choice
of treatment for common infections in diabetes. This may
result in advice to use first-line antibiotics for UTI for certain
patients, given over a longer period of time, and for others
second-line antibiotics. At the same time a tailored recom-
mendation for treatment of DM patients with LRTI should be
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